Key Product Details

Validated by

Biological Validation

Species Reactivity

Human, Mouse

Applications

Immunohistochemistry, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Sheep IgG
View all PEA-15 Primary Antibodies »

Product Specifications

Immunogen

E. coli-derived recombinant human PEA-15
Ala2-Ala130
Accession # Q15121

Specificity

Detects human and mouse PEA-15 in direct ELISAs and Western blots.

Clonality

Polyclonal

Host

Sheep

Isotype

IgG

Scientific Data Images for Human/Mouse PEA‑15 Antibody

Detection of Human PEA‑15 antibody by Western Blot.

Detection of Human PEA‑15 by Western Blot.

Western blot shows lysates of A172 human glioblastoma cell line and human cortex tissue. PVDF membrane was probed with 1 µg/mL of Sheep Anti-Human/Mouse PEA-15 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5588) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for PEA-15 at approximately 15 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.

PEA-15 antibody in Human Brain by Immunohistochemistry (IHC-P).

PEA‑15 in Human Brain.

PEA-15 was detected in immersion fixed paraffin-embedded sections of human brain (cortex) using Sheep Anti-Human/Mouse PEA-15 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5588) at 1 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Sheep HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS019) and counterstained with hematoxylin (blue). Specific staining was localized to neurons. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Detection of Human PEA-15 by Western Blot

Detection of Human PEA-15 by Western Blot

PED is inversely correlated to HNF4 alpha expression. (a) SNU-449 cells were co-transfected with 100 ng of pPED477 PED promoter-luciferase or pGL3 basic construct and treated with siRNA against HNF4 alpha or siRNA control. Luciferase activity was normalized for Renilla activity and is presented as mean±S.D. A representative experiment in triplicate is shown. (b,c) PED expression levels in HCC samples (b; n=59) or corresponding non-tumoral liver tissue (c, n=59) were correlated with HNF4 alpha expression. Correlation was calculated by Spearman test. Data are reported as probe intensity of an mRNA transcriptome array. (d) Western blot analysis for HNF4 alpha and PED in two HCC patient tumor samples and their corresponding non-tumoral (NT) tissues. Calnexin was used as loading control. Arrow: canonical full length HNF4 alpha (52 kDa); other bands are isoforms or truncated forms of the protein. (e,f) HuH-7 and PLC/PRF/5 cell lines were transfected with siRNA against HNF4 alpha (siHNF4 alpha ) or siRNA control. After 72 h the protein expression of HNF4 alpha and PED was measured by western blot (e) and beta -actin served as control. mRNA expression was measured by qPCR (f) using RNA 18 S as internal control at 48 h for HuH-7 and 72 h for PLC/PRF/5. Data are reported as mean±S.D. of two independent experiments performed in triplicate. (g) SNU-449 cells were transfected with siRNA against HNF4 alpha or siRNA against PED alone or in combination, or siRNA control, as indicated. Migration was assessed by CIM plate with xCELLigence apparatus after 12 h and 24 h. Data are reported as mean±S.D. of two independent experiments performed in triplicate. (h) Western blot analysis of pERKThr202/Tyr204 and ERK in SNU-449, Hep3B and HuH-7 cell lines transfected with PED-MYC. beta -Actin was used as loading control. (i) pERKThr202/Tyr204 expression in two HCC patients and their non-tumoral counterpart. Calnexin was used as loading control. *P<0.05, **P<0.01, ****P<0.0001 Image collected and cropped by CiteAb from the following publication (https://www.nature.com/articles/cddis2017512), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human PEA-15 by Western Blot

Detection of Human PEA-15 by Western Blot

PED confers resistance to sorafenib therapy. (a) HuH-7 and SNU-449 cells were transfected with siRNA against PED or siRNA control. Afterwards, HuH-7 and SNU-449 cells were treated with 10 μM and 20 μm respectively of sorafenib or left untreated. Cell growth was evaluated by using the xCELLigence instrument at the indicated time. Data are reported as mean±S.D. of two independent experiments performed in triplicate. (b) HuH-7 and Hep3B cells were transfected with PED-MYC vector for 24 h and then seeded in a 96-well plate. 10 μm of sorafenib was added and 24 h or 48 h later, cell viability was measured by a MTT assay. Data are reported as mean±S.D. of two independent experiments perfomed in triplicate. (c) HuH-7 cells were transfected with PED-MYC or empty vector (Ctrl) and siRNA against PED or siRNA control (Ctrl), as indicated. After 24 h, cells were treated with 10 μM or 7 μM sorafenib, respectively, for 48 h and caspase-3 activation was measured by western blot. (d) HuH-7 cells were transfected with siRNA against PED or control siRNA. Afterwards, cells were treated with 10 μM sorafenib and 48 h later caspase-3/7 assay activation was measured. Data are reported as mean±SD of one experiment performed in triplicate. *P<0.1, **P<0.01, ***P<0.001, ****P<0.0001 Image collected and cropped by CiteAb from the following publication (https://www.nature.com/articles/cddis2017512), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human PEA-15 by Western Blot

Detection of Human PEA-15 by Western Blot

PED is inversely correlated to HNF4 alpha expression. (a) SNU-449 cells were co-transfected with 100 ng of pPED477 PED promoter-luciferase or pGL3 basic construct and treated with siRNA against HNF4 alpha or siRNA control. Luciferase activity was normalized for Renilla activity and is presented as mean±S.D. A representative experiment in triplicate is shown. (b,c) PED expression levels in HCC samples (b; n=59) or corresponding non-tumoral liver tissue (c, n=59) were correlated with HNF4 alpha expression. Correlation was calculated by Spearman test. Data are reported as probe intensity of an mRNA transcriptome array. (d) Western blot analysis for HNF4 alpha and PED in two HCC patient tumor samples and their corresponding non-tumoral (NT) tissues. Calnexin was used as loading control. Arrow: canonical full length HNF4 alpha (52 kDa); other bands are isoforms or truncated forms of the protein. (e,f) HuH-7 and PLC/PRF/5 cell lines were transfected with siRNA against HNF4 alpha (siHNF4 alpha ) or siRNA control. After 72 h the protein expression of HNF4 alpha and PED was measured by western blot (e) and beta -actin served as control. mRNA expression was measured by qPCR (f) using RNA 18 S as internal control at 48 h for HuH-7 and 72 h for PLC/PRF/5. Data are reported as mean±S.D. of two independent experiments performed in triplicate. (g) SNU-449 cells were transfected with siRNA against HNF4 alpha or siRNA against PED alone or in combination, or siRNA control, as indicated. Migration was assessed by CIM plate with xCELLigence apparatus after 12 h and 24 h. Data are reported as mean±S.D. of two independent experiments performed in triplicate. (h) Western blot analysis of pERKThr202/Tyr204 and ERK in SNU-449, Hep3B and HuH-7 cell lines transfected with PED-MYC. beta -Actin was used as loading control. (i) pERKThr202/Tyr204 expression in two HCC patients and their non-tumoral counterpart. Calnexin was used as loading control. *P<0.05, **P<0.01, ****P<0.0001 Image collected and cropped by CiteAb from the following publication (https://www.nature.com/articles/cddis2017512), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human PEA-15 by Western Blot

Detection of Human PEA-15 by Western Blot

PED is inversely correlated to HNF4 alpha expression. (a) SNU-449 cells were co-transfected with 100 ng of pPED477 PED promoter-luciferase or pGL3 basic construct and treated with siRNA against HNF4 alpha or siRNA control. Luciferase activity was normalized for Renilla activity and is presented as mean±S.D. A representative experiment in triplicate is shown. (b,c) PED expression levels in HCC samples (b; n=59) or corresponding non-tumoral liver tissue (c, n=59) were correlated with HNF4 alpha expression. Correlation was calculated by Spearman test. Data are reported as probe intensity of an mRNA transcriptome array. (d) Western blot analysis for HNF4 alpha and PED in two HCC patient tumor samples and their corresponding non-tumoral (NT) tissues. Calnexin was used as loading control. Arrow: canonical full length HNF4 alpha (52 kDa); other bands are isoforms or truncated forms of the protein. (e,f) HuH-7 and PLC/PRF/5 cell lines were transfected with siRNA against HNF4 alpha (siHNF4 alpha ) or siRNA control. After 72 h the protein expression of HNF4 alpha and PED was measured by western blot (e) and beta -actin served as control. mRNA expression was measured by qPCR (f) using RNA 18 S as internal control at 48 h for HuH-7 and 72 h for PLC/PRF/5. Data are reported as mean±S.D. of two independent experiments performed in triplicate. (g) SNU-449 cells were transfected with siRNA against HNF4 alpha or siRNA against PED alone or in combination, or siRNA control, as indicated. Migration was assessed by CIM plate with xCELLigence apparatus after 12 h and 24 h. Data are reported as mean±S.D. of two independent experiments performed in triplicate. (h) Western blot analysis of pERKThr202/Tyr204 and ERK in SNU-449, Hep3B and HuH-7 cell lines transfected with PED-MYC. beta -Actin was used as loading control. (i) pERKThr202/Tyr204 expression in two HCC patients and their non-tumoral counterpart. Calnexin was used as loading control. *P<0.05, **P<0.01, ****P<0.0001 Image collected and cropped by CiteAb from the following publication (https://www.nature.com/articles/cddis2017512), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human PEA-15 by Western Blot

Detection of Human PEA-15 by Western Blot

PED is overexpressed in HCC samples. (a) PED expression levels in HCC samples and their matched non-tumoral (NT) counterpart measured by an mRNA gene expression microarray. Data are reported as probe intensity. (b) PED mRNA was measured by qRT-PCR in a separate cohort of 14 HCC patients and compared with the 10 available non-tumoral counterpart. 18 S was used as internal control and 2− delta delta Ct formula was applied to determine relative expression levels. Statistical analysis (a,b) with paired Student t-test. (c) Representative immunohistochemical staining from an HCC tumor (left) with positive (3+) PED staining and non-tumoral liver tissue (NT) showing negative PED staining (right). Scale bar=20 μm. (d) Percentage and h-score (staining intensity × percentage of positive tumor cells) of PED positivity in HCC samples and non-tumoral (NT) liver tissues by immunohistochemistry. (e) Western blot analysis of total PED and phosphorylated PED (PED S116 and PED S104) in two HCC patient samples and their corresponding NT control tissues. Calnexin was used as internal control. *P<0.05, ***P<0.001 Image collected and cropped by CiteAb from the following publication (https://www.nature.com/articles/cddis2017512), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human PEA-15 by Western Blot

Detection of Human PEA-15 by Western Blot

PED modulates cell migration. (a) Western blot analysis of PED protein expression in 10 different HCC cell lines. beta -Actin was used as loading control. (b) HuH-7 and SNU-449 cells were transfected with PED-MYC or an empty control vector as wells as with siRNA against PED (siRNA PED) or control siRNA. Cell growth properties were evaluated by using xCELLigence instrument at the time indicated. Data are reported as mean±S.D. of two independent experiments performed at least in triplicate. Difference was evaluated between PED overexpressing (PED-MYC), PED silenced (siRNA PED), empty vector transfected and a siRNA control transfected cells (two-way ANOVA test). (c) HLE, SNU-449 and HuH-7 cell lines were transfected with a vector overexpressing PED (PED-MYC) or empty control vector, siRNA against PED (siRNA PED) or siRNA control. Migration was assessed using a transwell assay after 24 h. One representative image of crystal violet stained cells at 100 × is shown above and quantification by colorimetry below. ***P<0.001, ****P<0.0001 Image collected and cropped by CiteAb from the following publication (https://www.nature.com/articles/cddis2017512), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human/Mouse PEA‑15 Antibody

Application
Recommended Usage

Immunohistochemistry

5-15 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human brain (cortex)

Western Blot

1 µg/mL
Sample: A172 human glioblastoma cell line and human cortex tissue

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: PEA-15

PEA-15 (Phosphoprotein Enriched in Astrocytes of 15 kDa) is a 15 kDa cytoplasmic protein that regulates cell proliferation and apoptosis. It is expressed in multiple cell types such as astrocytes; skeletal muscle and adipocytes. Human PEA-15 is 130 amino acids (aa) in length. It contains a death effector domain (aa 3‑81), plus two regulatory Ser phosphorylation sites. In a quiescent cell, it is either non-phosphorylated or constitutively phosphorylated at Ser116. Non-phosphorylated PEA-15 binds ERK, inhibiting cell proliferation. Phosphorylation at Ser116 promotes PEA-15 binding to FADD, blocking apoptosis. And activation-induced phosphorylation at Ser104 blocks PEA-15 binding to ERK, promoting cell proliferation. There is one potential alternate start site 21 aa upstream of the standard start site, and a second isoform that shows an Asn substitution for aa 36‑58. Full-length human and mouse PEA-15 show 99% aa identity.

Long Name

Phosphoprotein Enriched in Astrocytes 15

Alternate Names

HMAT1, HUMMAT1H, MAT1H, PEA15, PED

Entrez Gene IDs

8682 (Human); 18611 (Mouse); 364052 (Rat)

Gene Symbol

PEA15

UniProt

Q15121 (Human)

Additional PEA-15 Products

Product Documents for Human/Mouse PEA‑15 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human/Mouse PEA‑15 Antibody

For research use only

Citations for Human/Mouse PEA‑15 Antibody

Customer Reviews for Human/Mouse PEA‑15 Antibody

There are currently no reviews for this product. Be the first to review Human/Mouse PEA‑15 Antibody and earn rewards!

Have you used Human/Mouse PEA‑15 Antibody?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies